Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added these.
Got it.
Yes, I saw it in there, but I want to hear it from Armens mouth. Lol
What info you want? Ask your questions.
1 of my questions I want to be certain on even though I am pretty sure of per details in proxy. Is will the 75 million shares in incentive plan,be part of any RS ratio as well. Secondly is that just a set aside incentive program, where overtime people can earn the incentives or buy shares, or are they intended to be just handed out in one lump sum like last time.
I think it is a good question to ask.
Why are you not lowering the authorized share count?
Although it really wouldn't be that high of an AS with or without a change.
Got it
Good question. Will add to list.
I'll get these added.
Added to list.
Have added, good questions.
I think we should start a list of questions here. If you develop here, I can submit to Stuart Smith.
New job going great! Needed the change, now we got the change we needed with RXMD as well. S1, let's continue the push for making this company presentable to institutional investors.
Looks like we are getting the conference call we needed, but would have been nice to have prior to creating the proxy so we could make adjustments. Still all been great news this week thus far.
I will be looking to rejoining the communication here now that they have finally shown us they can be held to their word of submitting an S1 Registration application. Thanks to those of you who kept up the persistent support here.
Who you referencing exactly?
Exactly, what can they say? What a disastrous PROXY!
I'm ready! This just got real interesting again. They got my undivided attention now. What is actually going on behind closed doors @ RXMD? Who's taking the reins?
I am thinking the quietness from the usually very transparent CEO is a good thing for RXMD and it's shareholders. I like them will remain quiet until they produce a SEC Filing or let us in on this big event. GL everyone and thanks for keeping the board great. I do believe 2020 is the year yet for getting some of things we have always wanted for this company accomplished.
Yah, he is up late. Lol. But this truly is something they need that will impact the bottom line immensely. Makes the company even more desirable at this point.
PBMs and their DIR FEES, about to come to an end.
.@realDonaldTrump signs executive orders aimed at lowering prescription drug costs.
“The middlemen are making a fortune and pharmacy benefit managers and people are just bilking Medicare patients with these high drug prices."
https://t.co/VQjiz26TnB
Trump also revived a 2019 rule that never came to fruition after pushback from pharmacy benefit managers, which negotiate drug prices with insurers. The proposed rule would require PBMs in Medicare Part D to pass discounts negotiated with insurers directly to the patients using those drugs, allowing Medicare beneficiaries to save money on medications.
Trump said Friday that his new executive order would cut out the “middlemen" and "middlewomen” and directed Health and Human Services Secretary Alex Azar to “complete the rule-making process he commenced.”
Just as they did in 2019, pharmacy benefit managers are expected to retaliate. The PBM sector has planned an ad campaign to oppose any effort to eliminate rebates and play it as a political mistake that could raise drug costs for the elderly in swing states ahead of the November election, Politico reported.
“The middlemen are making a fortune, and pharmacy benefit managers and people are just bilking Medicare patients with these high drug prices while they pocket gigantic discounts, gigantic discounts,” he said.
The president will also implement a mandate that pharmaceutical companies sell prescription drugs in the U.S. at the same prices as in other countries, called the international drug-pricing index or the “favored nations clause.” Trump has long decried what he calls a "global freeloading" system in which drug companies are able to offer their products at a lower cost to other countries by charging the U.S. more. He first proposed the initiative in July 2019.
“It also means that the U.S. taxpayers are effectively subsidizing the socialist healthcare systems of foreign welfare states and many other countries,” Trump said. “We will end that abuse and restore the principles of free enterprise. ... This has to do with common sense and courage, to be honest.”
Trump said he’ll be meeting with executives from the pharmaceutical industry Tuesday to discuss ways to lower drug prices and out-of-pocket expenses. He added that if the talks are “successful,” the fourth executive order could be scrapped.
Your welcome. Sorry I had to type up from my phone, didn't have computer available to make it more detailed. But all those baseline numbers come from 3/31 FS. So anyone can verify. Happy investing everyone. This is as fabulous longterm stock.
Well this stock is unusual then. Because last time note holders were converting shares this stock ran to it's all time high of $.267. Yes it went from $.01 to $.267 while converting like 13 million shares. That is the beauty of the leak out clause, it doesn't affect the price when good volume exists.
DEBT BALANCE
Doing some math, I would suspect Note balance for acquisitions of $18 million revenue business and loan for expansion initiatives to have been $4.37 million at 3/31/20, that includes accrued interest. If 20 million shares have been converted since 3/31/20, I would expect roughly $0.8 to $1 million in debt has been eliminated since then. 20 million is assuming 10 million restricted was returned to treasury from the acquisition deal restructuring based on current O/S of 364.5 million and O/S of 354.3 million on 5/15/20 per F/S. Therefore debt balance in the neighborhood of $3.3 to 3.5 million.
CONVERSION OUTLOOK
The higher the price rises, the less shares get converted. As Stockforce stated, the company intends on refinancing once they file S1 and can obtain better financing. 10% leakout clause is always in play though. It's not going to slow this thing down at all with the right news.
The acquisition he spoke of was for a business producing $18 million in annual net revenues, that we bought for like $1.9 million.
They acquire shares in exchange for a certain amount. They can then sell those shares at any price. Catch is, they can only hold a small number of shares at any time. So if they get 3 million shares for example they have to sell all those before getting any more shares. So hanging onto them for a price increase, the next shares will be exchanged at a much higher price, and same scenario.
I got a trip planned to Miami next summer, and was telling my wife I am visiting PharmcoRx on my layover day.
I don't have any sell orders in. I am fully expecting this company to go to NASDAQ, and this year.
My TDAmeritrade and Fidelity 401k had a very nice uptick today. More to come.
Absolutely right. 100% love your takes.
Maxing out the O/S means that they would get the O/S to 1 billion. That's the only max on the O/S, what other O/S max is there? Now if you said they were looking to clear out debt prior to S1, I could fall in line with that comment.
What's the A/S amount? Yah, 1,000,000,000, Current O/S 464 million. so you think what again! SMH
That 10,000,000 was issued to FPRX for tha aquisition,but then later returned when they restructured the deal last September, they have been waiting for some finalization of a few documents to be able to return those 10,000,000 to RXMDs treasury. Should reduce OS by 10 million.
I have prepared for this year and period for 5 years now. By preparing, I mean buying shares, doing DD, providing DD, and supporting this company and their management. They have shareholders interest and ongoing business growth at the forefront of their gameplan.
Yep $,50 for starters. I want to see NASDAQ behind the RXMD ticker symbol.
I am for sure down with that plan. RXMD is setting the course for us.
I am holding shares, a bunch of them. Just patiently waiting for more news thats gets us to stepping up to NASDAQ later this year.
Oleg Firer, RXMD'S Independent Director, is CEO/Owner of Net Element NETE
This company has set the stage for something very big here. They are positioning the pieces. I can't say for sure what the end move is for the checkmate, but they got something they are excited about that was worth the wait. Pieces so far:
1. 3 years Audited Financial Statements
2. Transitioned to new SEC auditing FIRM just over a week ago.
3. Hired new Investment Banking FIRM.
4. In process of completing a 180 page S1 prior to the end of July and filing with SEC.
5. Taking advantage of a big opportunity that came up in last few months.
6. Revenues held really strong during COVID months.
Great summation their stockforce, just stating what all of us longterm investors know to be true. RXMD will succeed for us, it's employees, and customers. When exactly is the only question that needs to be answered yet! Great work and thanks for awesome DD. I have been super busy in new job, so my time has been limited. Looking forward to this S1 and any other news that follows.
Yah that was the other company, we wouldn't be doing anything with them.